Treatment outcome of adult patients with Burkitt lymphoma: Results using the LMB protocol in Korea

Annals of Hematology

Volumn 88, Issue 11, 2009, Pages 1099-1106

  Choi, Moon Ki ^a   Jun, Hyun Jung ^a   Lee, Sung Yoon ^a   Kim, Kyung Ha ^a   Lim, Do Hyoung ^a   Kim, Kihyun ^a   Ko, Young Hyeh ^a   Kim, Won Seog ^a   Kim, Seok Jin ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Burkitt lymphoma; Chemotherapy; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW METASTASIS; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; KOREA; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; ADOLESCENT; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG SCREENING; HEMATOLOGIC DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG EVALUATION; ETOPOSIDE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIERS ESTIMATE; KOREA; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 70349421053     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0729-3     Document Type: Article

References (23)

1. Magrath I (1990) The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 55:133-270. doi: 10.1016/S0065-230X(08) 60470-4
2. Bishop PC, Rao VK, Wilson WH (2000) Burkitt's lymphoma: Molecular pathogenesis and treatment. Cancer Invest 18:574-583. doi: 10.3109/ 07357900009012197
3. Kian TC, Miriam T, Richard Q et al (2008) Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk Lymphoma 49:824-827. doi: 10.1080/10428190701882948
4. Park YH, Kim WS, Kang HJ et al (2006) Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. Ann Hematol 85:285-290. doi: 10.1007/s00277-005-0050-8
5. Blum KA, Lozanski G, Byrd JC (2004) Adult Burkitt leukemia and lymphoma. Blood 104:3009-3020. doi: 10.1182/blood-2004-02-0405
6. Ferry JA (2006) Burkitt's lymphoma: Clinicopathologic features and differential diagnosis. Oncologist 11:375-383. doi: 10.1634/ theoncologist.11-4-375
7. Divine M, Lepage E, Briere J et al (1996) Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. Groupe Etude Lymphomes Adulte J Clin Oncol 14:240-248
8. Longo DL, Duffey PL, Jaffe ES et al (1994) Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: A high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol 12:2153-2159
9. Patte C, Philip T, Rodary C et al (1986) Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: Results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4:1219-1226
10. Patte C, Auperin A, Michon J et al (2001) The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370-3379. doi: 10.1182/blood.V97.11.3370
11. Philip T, Meckenstock R, Deconnick E et al (1992) Treatment of poor prognosis Burkitt's lymphoma in adults with the Societe Francaise d'Oncologie Pediatrique LMB Protocol-a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC). Eur J Cancer 28A:1954-1959. doi: 10.1016/0959-8049(92) 90235-T
12. Divine M, Casassus P, Koscielny S et al (2005) Burkitt lymphoma in adults: A prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 16:1928-1935. doi: 10.1093/annonc/ mdi403
13. Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
14. Soussain C, Patte C, Ostronoff M et al (1995) Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85:664-674
15. Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 7:332-339
16. Patte C, Philip T, Rodary C et al (1991) High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123-132
17. Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44:1083-1105. doi: 10.1177/ 0091270004268128
18. Lee EJ, Petroni GR, Schiffer CA et al (2001) Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: Results of cancer and leukemia group B study 9251. J Clin Oncol 19:4014-4022
19. Thomas DA, Cortes J, O'Brien S et al (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470
20. Lopez TM, Hagemeister FB, McLaughlin P et al (1990) Small noncleaved cell lymphoma in adults: Superior results for stages I-III disease. J Clin Oncol 8:615-622
21. Mead GM, Barrans SL, Qian W et al (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/ NCRI LY10 trial). Blood 112:2248-2260. doi: 10.1182/blood-2008-03-145128
22. Thomas DA, Faderl S, O'Brien S et al (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580. doi: 10.1002/cncr.21776
23. Mead GM, Sydes MR, Walewski J et al (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274. doi: 10.1093/annonc/mdf253